ABT

Stock futures opened higher on October 21st, 2026, as bond yields and oil prices cooled from recent highs. SpaceX surged 8% after posting impressive Q3 earnings with 161% revenue growth. Mixed earnings from NEE, ABT, and CME set the stage for major Mag 7 earnings releases after the close, with Meta and Tesla expected to report results amid ongoing market scrutiny.

Abbott reported Q3 2026 earnings of $1.42 per share, missing the consensus estimate of $1.43, though revenues of $13.01 billion exceeded expectations. The company has underperformed the S&P 500 by 18.2% year-to-date.

Despite the earnings miss, Abbott maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends. The Medical-Products industry ranks in the bottom 36% of Zacks industries.

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline.

Abbott (ABT) closed at $101.82, up 2.23%, outperforming the S&P 500's 0.06% decline. The company is expected to report Q3 earnings on October 21, 2026, with projected EPS of $1.42 (up 9.23% YoY) and revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank #2 (Buy) rating and trades at a Forward P/E of 18.04, below its industry average of 19.61.

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield.

Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

Abbott Laboratories is positioned for significant growth potential, with analyst projections suggesting the stock could reach approximately $210 per share by 2036 based on conservative 8% annual earnings growth. The healthcare company's strong track record includes a 9.7% compound annual earnings-per-share growth rate over the past decade, bolstered by strategic acquisitions. Abbott's status as a Dividend King with 54 consecutive years of dividend increases, combined with a 2.5% dividend yield, makes it an attractive option for income-focused investors seeking defensive holdings with upside potential.

The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.

Abbott Laboratories has attracted investor attention recently. The stock declined 6.2% over the past month, underperforming the S&P 500's +1.4% gain.

Abbott is expected to post 10% year-over-year earnings growth for the current quarter with revenue growth of 13.5%. The company has a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. Abbott's valuation is rated C, indicating it trades at par with peers.

Abbott (ABT) declined 1.94% to $98.16, underperforming the S&P 500's 0.58% gain. The stock has lost 7.6% over the past month.

The company is expected to report Q3 earnings on October 21, 2026, with anticipated EPS of $1.43 (up 10% YoY) and revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank #2 (Buy) rating with a Forward P/E of 18.13, trading at a discount to its industry average.

Europe's Point of Care (POC) Diagnostics Market is projected to grow from US$8.9 billion in 2024 to US$21.4 billion by 2031, with a 13.4% CAGR driven by rapid testing innovation, molecular diagnostics advancement, and increasing prevalence of infectious and chronic diseases. Germany leads the regional market, supported by strong healthcare infrastructure and public health initiatives. Key players include Siemens AG, Abbott Laboratories, Roche, bioMerieux, Bio-Rad, QIAGEN, Nova Biomedical, Polymer Technology Systems, and Danaher Corp.

The article examines successful long-term investors like Ronald Read, Anne Scheiber, and Grace Groner who built million-dollar portfolios by holding blue-chip stocks for 50+ years and reinvesting dividends. It highlights three stocks favored by these investors: Wells Fargo, Abbott Laboratories, and AbbVie, emphasizing the power of compounding and patience in wealth building.

Dexcom released its 2026 State of Type 2 Report highlighting significant gaps in CGM awareness and reimbursement access, with 55% of Type 2 diabetes patients having limited knowledge of the technology. However, the report reveals substantial growth opportunities as 58% of Type 2 patients on GLP-1 medicines use CGM, and a majority are open to CGM when recommended alongside GLP-1 therapy. Competitors Abbott Laboratories and MiniMed are also expanding their CGM portfolios with innovative features and sensor technologies.

With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

Abbott stock closed down 2.1%, underperforming the S&P 500's 0.25% loss. The stock has declined 7.33% over the past month, significantly lagging the Medical sector.

Upcoming earnings are expected to show $1.43 EPS (10% YoY growth) and $12.91B revenue (13.52% increase). Abbott holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.28, trading at a discount to its industry average.

Catheter Precision, a subsidiary of Flyte Aviation (NYSE American: VJET), published a peer-reviewed study in The Journal of Interventional Cardiology demonstrating that its LockeT suture retention device outperforms Abbott's Perclose vascular closure device. The 172-patient study showed LockeT achieved 1.2% access-site complications versus 9.3% for Perclose, with zero device failures compared to 4.7% for Perclose, while maintaining equivalent efficiency in hemostasis and same-day discharge rates.

Abbott announced plans to spin off its nutrition business into an independent public company, focusing on higher-margin medical technologies and diagnostics. The company reported 7% year-over-year comparable sales growth in Q3 2026, with cancer diagnostics sales up 14% driven by Cologuard and new blood-based colorectal cancer screening tests. Pulsed field ablation technology is accelerating growth in electrophysiology, positioning Abbott for accelerated growth beyond historical rates.

Markets open higher ahead of major Mag 7 earnings reports. SpaceX posts impressive Q3 results with 161% revenue growth.

Early morning earnings from NextEra Energy, Abbott Labs, and CME Group show mixed results, with Abbott declining on nutrition spinoff concerns. Meta and Tesla earnings expected after close, with Meta facing -52.4% earnings decline despite strong revenue growth, while Tesla carries a Sell rating heading into its report.

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model.